 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates ADCs for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, March 18, 2021 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2020 and prov 